Skip to main content
OpenTrials
Completed

NCT Number: NCT00699114

Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain

The purpose of this placebo controlled clinical trial is to evaluate the dose response relationship of ibuprofen in doses from 400 mg to 800 mg and paracetamol (acetaminophen)in doses from 500 mg to 1000 mg compared with paracetamol (acetaminophen)1000 mg plus codeine 60 mg on acute postoperative pain after surgical removal of impacted third molars.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–30 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital

Oslo, N-0407, Norway

About this study

Acetaminophen (paracetamol) and related aspirin-like drugs have traditionally been used for pain control of minor to moderate postoperative pain. Gradually traditional non-steroidal anti-inflammatory drugs (NSAIDs) have become more popular as analgesics due to assumed superior therapeutic effects and aggressive marketing campaigns orchestrated by the pharmaceutical industry.

Ibuprofen is a widely used analgesic both in non-prescription and prescription doses.

A dose-response relationship for low ibuprofen doses is shown. Evidence of a progressing dose response relationship for moderate (i.e. 400 mg) to higher doses is scarce. A possible analgesic ceiling effect has been suggested for doses above 400 mg, although a correlation between given ibuprofen doses above 400 mg and patient serum levels is shown. However, it may be questioned if the plasma concentration of ibuprofen is an important determinator of analgesic drug efficacy. A higher dose is more likely to influence the duration of analgesic effect rather than the peak analgesic effect.

There are few clinical trials investigating the dose-response relationship of increasing ibuprofen doses and paracetamol doses. To our knowledge no published study has investigated the dose-response relationship of ibuprofen and paracetamol in the same trial with a negative (i.e. placebo) and a positive (i.e. best standard analgesic treatment) control group.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of both sexes referred for surgical removal of impacted third molars, due to symptoms or after being advised to do so by their dentist.
  • Persons of both sexes (ASA type I).
  • Females who are not pregnant or plan conception.
  • Persons who have not used analgesics for 3 days prior to the day of surgery.
  • Persons without known active ulcus or gastrointestinal bleeding.
  • Persons without any known hypersensitivity for NSAIDs.
  • Persons under no other continuous drug treatment than contraceptives.
  • Caucasian origin.
  • Persons with at least moderate postoperative pain as defined by subjective score on a verbal rating scale after surgical removal of third molars.

Exclusion criteria

  • Patients with surgery time exceeding 60 minutes
  • Peroperative complications such as profuse bleeding or perforation to the maxillary sinus requiring additional drug treatment during or after the surgical removal of the third molar.
  • Postoperative complications such as extended bleeding, nausea and regurgitation during the observation period.
  • Smoking before taking the test-drug or during the observation period.

Treatment and study plan

Placebo

Drug

Lactose as powder in gelatine capsules, single dose

Other names: Lactose

Ibuprofen 400 mg

Drug

Ibuprofen 400 mg as powder in gelatine capsules, single dose

Other names: M01A E01 Ibuprofen

Ibuprofen 600 mg

Drug

Ibuprofen 600 mg as powder in gelatine capsules, single dose

Other names: M01A E01 Ibuprofen

Ibuprofen 800 mg

Drug

Ibuprofen 800 mg as powder in gelatine capsules, single dose

Other names: M01A E01 Ibuprofen

Paracetamol (acetaminophen) 500 mg

Drug

Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose

Other names: N02B E01 Paracetamol (acetaminophen)

Paracetamol (acetaminophen) 1000 mg

Drug

Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose

Other names: N02B E01 Paracetamol (acetaminophen)

Paracetamol (acetaminophen) 1000 mg + codeine 60 mg

Drug

Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose

Other names: N02B E01 Paracetamol (acetaminophen) + R05D A04 codeine

Primary outcomes

  1. Sum Pain Intensity Score(SPI)

    Time frame: 3 hour observation period

Secondary outcomes

  1. Sum Pain Intensity Difference Score (SPID)

    Time frame: 3 hours

  2. Sum Pain Intensity Score (SPI)

    Time frame: 6 hours

  3. Sum Pain Intensity Difference Score (SPID)

    Time frame: 6 hours

  4. Maximum Pain Intensity Difference Score (MAXPID)

    Time frame: Unknown, calculated variable

  5. Time to Maximum Pain Intensity Difference Score

    Time frame: Unknown, calculated variable

  6. Self-reported Occurrence of Adverse Effects

    Time frame: 3 hours

  7. Self-reported Occurrence of Adverse Effects

    Time frame: 6 hours

Sponsors and collaborators

Lead sponsor

Ullevaal University Hospital

Other

Collaborators

  • University of Oslo

Registry information

Official study title

Analgesic Effect of Ibuprofen 400, 600 and 800 mg, Paracetamol 500 and 1000 mg, and Paracetamol 1000 mg Plus 60 mg Codeine: Single-dose, Randomized, Placebo-controlled and Double-blind Study on Acute Pain After Third Molar Surgery

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Jun 17, 2008
Registry last updated
Jul 6, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.